Merck launches online platform fertility.com
- Details
- Category: Merck Group
Merck, a leading science and technology company, today announces the launch of the new online portal fertility.com. Fertility.com is the entrance to access two unique and bespoke portals:
- Fertility.com/hcp; developed for fertility Healthcare Professionals (HCPs)
- Fertility.com/support; created for women, men and couples who are looking for information about fertility and/or are undergoing fertility treatment
Roche commences tender offer for all shares of Foundation Medicine, Inc. for US$ 137.00 per share in cash
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of Foundation Medicine, Inc. (NASDAQ: FMI) at a price of US$ 137.00 per share. The tender offer is being made pursuant to the previously announced merger agreement dated as of 18 June 2018 among Foundation Medicine, Inc., Roche Holdings, Inc., an indirect wholly owned subsidiary of Roche Holding Ltd, and 062018 Merger Subsidiary, Inc., a wholly owned subsidiary of Roche Holdings, Inc.
Global study by Novartis and European Migraine and Headache Alliance reveals 60% of employed people with severe migraine miss, on average, a week of work per month
- Details
- Category: Novartis
Novartis and the European Migraine and Headache Alliance (EMHA) announced initial findings from the largest global migraine patient study to date, involving over 11,000 people from 31 countries. Migraine is a neurological disease which can vary in severity with symptoms ranging from head pain, nausea, vomiting to sensitivity to light.
Amgen and Novartis present new data demonstrating long-term efficacy, safety and tolerability of Aimovig TM (erenumab-aooe) in patients with chronic and episodic migraine
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) today announced that the results of two open-label extension (OLE) studies of AimovigTM (erenumab-aooe) in patients with chronic and episodic migraine, respectively, will be presented at the 60th Annual Scientific Meeting of the American Headache Society (AHS) in San Francisco. Results from a one-year study in chronic migraine patients reinforced the established safety and efficacy profile of Aimovig in long-term use.
Novartis Clear about Psoriasis survey data highlights challenges psoriasis patients face to achieve goal of clear skin
- Details
- Category: Novartis
Novartis announced today the publication of global Clear about Psoriasis survey data in the Journal of the European Academy of Dermatology and Venereology[1]. The publication highlights that despite clear or almost clear skin being more achievable than ever before, patients may face a long journey to attain this reality[1].
Roche and Foundation Medicine reach definitive merger agreement to accelerate broad availability of comprehensive genomic profiling in oncology
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) and Foundation Medicine, Inc. (NASDAQ: FMI) have entered into a definitive merger agreement for Roche to acquire the outstanding shares of FMI's common stock not already owned by Roche and its affiliates at a price of US$ 137.00 per share in cash. This corresponds to a total transaction value of US$ 2.4 billion on a fully diluted basis, and a total company value of US$ 5.3 billion on a fully diluted basis.
Breast cancer is one of the most common cancers in China - and it is on the rise
- Details
- Category: Business and Industry
Among women in China, rates of breast cancer rose around 3.5% each year between 2000 and 2013. In comparison, breast cancer among American women decreased by about 0.4% a year over the same timeframe. China's rapid urbanisation and development of multiple 'megacities' - a city with 10 million or more inhabitants - reveals higher rates of breast cancer in urban areas, and in more densely-populated areas.
More Pharma News ...
- Kallyope and Novo Nordisk announce collaboration to discover novel therapeutics for obesity and diabetes
- Alcon AcrySof® IQ PanOptix® trifocal intraocular lens shows superior visual performance in head-to-head trial post-cataract surgery
- New long-term data confirm Roche’s Gazyva/Gazyvaro extends the lives of people with chronic lymphocytic leukaemia compared to MabThera/Rituxan
- Pfizer announces extension of Zithromax® Antibiotic Donation Program through 2025 to help eliminate world's leading infectious cause of blindness
- Update on Phase III clinical trials of lanabecestat for Alzheimer's disease
- Amgen, Oklahoma Health Care Authority and University of Oklahoma's Pharmacy Management Consultants partner to improve medicaid outcomes
- FDA grants Priority Review to Roche’s Hemlibra for people with haemophilia A without factor VIII inhibitors